Neoleukin Therapeutics
Neoleukin Therapeutics is a Seattle-based, publicly traded clinical-stage pharmaceutical company (NASDAQ: NLTX) developing medicines for serious immunological disorders. Founded in 2003, it employs 51-100 people and is funded primarily through equity financings.
- Company typePublic
- Founded2003
- HeadquartersSeattle, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Neoleukin Therapeutics does
Neoleukin Therapeutics is a publicly traded, clinical-stage pharmaceutical company (NASDAQ: NLTX) headquartered in Seattle, Washington, focused on developing medicines to treat serious immunological disorders. Founded in 2003, the company employs between 51 and 100 people and operates as an independent, publicly-held entity with no disclosed parent company or subsidiary structure.
The company's leadership team is anchored by founder and CEO Jonathan Drachman and includes Chief Medical Officer Priti Patel, Vice President and Head of Research Bill Arthur, Director of Computational Technology Javier Castellanos, and Principal Scientist Ryan Swanson. The inclusion of a dedicated computational technology role indicates that computational biology is part of the discovery workflow, although specific product candidates, platforms, or modalities are not disclosed in the input data. No approved products, named customers, or commercialization milestones are referenced, consistent with a pre-commercial development stage.
Capitalization has been driven primarily by equity financings, with approximately $86.2M raised in December 2019 and $71.4M raised in July 2020, for cumulative disclosed funding of roughly $157.6M over an 18-month window. As a clinical-stage biotech, the business model is currently R&D-driven rather than revenue-generating: the company funds operations through equity capital and is expected to monetize through future product sales, licensing, or partnership deals once pipeline assets advance to commercialization.
Neoleukin Therapeutics firmographics
Firmographics- Name
- Neoleukin Therapeutics
- Legal name
- Neoleukin Therapeutics
- Website
- https://neoleukin.com
- Company type
- Public
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Neoleukin Therapeutics is a Seattle-based, publicly traded clinical-stage pharmaceutical company (NASDAQ: NLTX) developing medicines for serious immunological disorders. Founded in 2003, it employs 51-100 people and is funded primarily through equity financings.
- Ownership category
- akta.pro rank
Neoleukin Therapeutics industry classification
Industry- Product category
- Biopharmaceuticals
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics) (HLAAAIAH)
Keywords
Where Neoleukin Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Seattle
- HQ country
- United States
- HQ region
- North America
Markets served
Neoleukin Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Others
Neoleukin Therapeutics product offering
Product offeringCore offering
Neoleukin Therapeutics is a pharmaceutical company that develops medicines to treat serious immunological disorders. The company focuses on creating novel therapeutic candidates using protein engineering and computational design approaches for clinical-stage drug development.
Differentiator
Problem solved
Functional benefit
Companies that use Neoleukin Therapeutics
Customer profileIdeal customer profiles1 record
Neoleukin Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Neoleukin Therapeutics partnerships and signals
Strategic signalRecent moves3 records
Expansion highlights3 records
Neoleukin Therapeutics competitors and assessment
Company assessmentMarket position
Competitive moat2 records
Key risks5 records
Key highlights5 records
Customer concentration
Neoleukin Therapeutics social profiles
Digital presenceNeoleukin Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neoleukin Therapeutics leadership team
Management profileNumber of profiles
Profiles5 records
Neoleukin Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neoleukin Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neoleukin Therapeutics
What does Neoleukin Therapeutics do?
Neoleukin Therapeutics is a pharmaceutical company that develops medicines to treat serious immunological disorders. The company focuses on creating novel therapeutic candidates using protein engineering and computational design approaches for clinical-stage drug development.
Is Neoleukin Therapeutics a public or private company?
Neoleukin Therapeutics is a public company. It is classified as public and is currently operating.
When was Neoleukin Therapeutics founded?
Neoleukin Therapeutics was founded in 2003. It employs 51 to 100 people.
Where is Neoleukin Therapeutics based?
Neoleukin Therapeutics is headquartered in Seattle, United States, in the North America region.
Does Neoleukin Therapeutics have an API?
No public API is recorded for Neoleukin Therapeutics.
What industry is Neoleukin Therapeutics in?
Neoleukin Therapeutics's product category is Biopharmaceuticals. Its primary akta.pro industry code is HLAAAAAJ, Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.